Atenolol/hydrochlorothiazide/ramipril/simvastatin - Cadila Pharmaceuticals

Drug Profile

Atenolol/hydrochlorothiazide/ramipril/simvastatin - Cadila Pharmaceuticals

Alternative Names: Hydrochlorothiazide/ramipril/simvastatin/atenolol - Cadila Pharmaceuticals; Polycap 4; Ramipril/simvastatin/atenolol/hydrochlorothiazide - Cadila Pharmaceuticals; Simvastatin/atenolol/hydrochlorothiazide/ramipril - Cadila Pharmaceuticals

Latest Information Update: 11 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cadila Pharmaceuticals
  • Class Antihyperlipidaemics; Antihypertensives; Benzothiadiazines; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; HMG-CoA reductase inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 31 Jan 2014 Launched for Cardiovascular disorders (prevention) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top